Poteligeo (mogamulizumab) vs Ukoniq (umbralisib)

Poteligeo (mogamulizumab) is a monoclonal antibody that targets the C-C chemokine receptor 4 (CCR4) and is approved for the treatment of certain types of cutaneous T-cell lymphoma (CTCL), specifically for patients who have received at least one prior systemic therapy. Ukoniq (umbralisib) is a dual inhibitor of PI3K-delta and CK1-epsilon, indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for follicular lymphoma (FL) after at least three prior systemic therapies. When deciding between these two medications, it is crucial to consider the specific type of lymphoma being treated, as well as the patient's prior treatment history and potential side effects, with guidance from a healthcare professional who can provide personalized medical advice based on the patient's individual health profile.

Difference between Poteligeo and Ukoniq

Metric	Poteligeo (mogamulizumab)	Ukoniq (umbralisib)
Generic name	mogamulizumab-kpkc	umbralisib
Indications	Adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy	Adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies
Mechanism of action	CCR4-directed monoclonal antibody	PI3K delta and CK1-epsilon inhibitor
Brand names	Poteligeo	Ukoniq
Administrative route	Intravenous infusion	Oral
Side effects	Rash, infusion reactions, fatigue, diarrhea, musculoskeletal pain, and upper respiratory tract infection	Nausea, diarrhea, fatigue, anemia, vomiting, and increased liver enzymes
Contraindications	None known	None known
Drug class	Monoclonal antibody	Small molecule kinase inhibitor
Manufacturer	Kyowa Kirin Co., Ltd.	TG Therapeutics, Inc.

Efficacy

Efficacy of Poteligeo (mogamulizumab) for Lymphoma

Poteligeo (mogamulizumab) is a monoclonal antibody that has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS), which are types of cutaneous T-cell lymphoma (CTCL). The efficacy of mogamulizumab was established in a pivotal clinical trial known as the MAVORIC study. This phase III trial demonstrated that mogamulizumab significantly improved progression-free survival (PFS) compared to vorinostat in patients with MF and SS who had received at least one prior systemic therapy.

In the MAVORIC trial, the median PFS for patients treated with mogamulizumab was markedly longer than for those who received vorinostat. Additionally, a higher proportion of patients treated with mogamulizumab achieved an objective response. The response was also more durable with mogamulizumab, indicating its efficacy in providing not only a higher response rate but also a more sustained treatment effect for patients with these challenging forms of lymphoma.

Efficacy of Ukoniq (umbralisib) for Lymphoma

Ukoniq (umbralisib) is a kinase inhibitor approved by the FDA for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for adult patients with follicular lymphoma (FL) who have received at least three prior systemic therapies. The approval of umbralisib for these indications was based on the results of the UNITY-NHL trial, a single-arm, multi-cohort, open-label, multicenter trial.

In the UNITY-NHL trial, the efficacy of umbralisib was evaluated in patients with relapsed or refractory MZL and FL. The results showed that umbralisib achieved a meaningful overall response rate (ORR) in both MZL and FL patient populations. The duration of response (DOR) for patients who responded to umbralisib treatment was also notable, with many patients maintaining their response for a significant period. This data supports the use of umbralisib as an effective treatment option for patients with MZL and FL who have exhausted other therapies.

Regulatory Agency Approvals

Poteligeo

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Therapeutic Goods Administration (TGA), Australia

Ukoniq

Food and Drug Administration (FDA), USA

Access Poteligeo or Ukoniq today

If Poteligeo or Ukoniq are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Poteligeo

Buy Ukoniq

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: